LAMC3

Across TCGA pan-cancer cohorts, LAMC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LAMC3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LAMC3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAMC3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where LAMC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	46	view →
LUAD	DFS	Median	All	0.873	0.957	.002	19	view →
PDAC	DFS	Median	III,IV	0.970	0.348	.003	18	view →
HNSC	OS	Tertile	II,III,IV	0.949	1.000	.030	4	view →
LSCC	DFS	Median	II,III,IV	0.990	0.853	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LAMC3–CCRCC (DFS)

Open the CCRCC breakdown →